Severe Adverse Effects Associated with Multidrug Resistant Tuberculosis Medications among Patients attending ALERT Hospital, Ethiopia.
Background: Ethiopia is one of the countries with high MDR-TB burden. MDR-TB medications have sever adverse effects. However, little is known about adverse effects of MDR-TB medications in Ethiopia. Therefore this study is aimed at determining incidence of severe adverse effects associated with MDR-TB therapy.
Methods: A cross sectional study design using retrospective medical record review of 238 patients with Drug-Resistant Tuberculosis was conducted. Applying multiple logistic regression models, adjusted odds ratio and their 95% confidence intervals were used to select important risk factors associated with treatment adverse effects.
Results: One or more adverse effects developed in 219 cases (92 %). These effects led the clinicians to suspend one or more drugs from the treatment regimen in 46 cases (19.3%). Adverse effects observed most frequently include: Gastrointestinal Effect (79.4%), Hypokalemia (49.3%), Arthralgia (32%), Sleep Disturbance (13.7%), Psychosis (8.2%), Hypothyroidism (6.4%), Renal Toxicity (5.6%), Neuropathy (3.7%), and Hepatotoxicity (0.9%). Co morbid conditions of HIV/AIDS, and diabetes mellitus, older age group and homelessness were identified as important predictors of sever adverse effect.
Conclusion: Sever adverse reactions to MDR-TB therapy were common, and resulted in suspension of one or more drugs. We suggest that efforts should be made to continue treatment in the face of adverse effects. All diagnostic procedures and ancillary medications need to be always available for early detection, treatment and follow up of adverse events. Special attention should be given for elderly, homeless, HIV/MDR-TB, and Diabetes/MDR-TB co- infected patients.
Key words: Sever Adverse Effect, MDR-TB therapy, ALERT Hospital, Ethiopia
List of references
Federal Ministry of Health of Ethiopia (FMOH). Health sector development program IV, annual performance report, EFY 2007 (2014/15); version 1
World Health Organization (WHO). Multidrug and extensively drug-resistant TB (M/XDR-TB): Global report on surveillance and response. Geneva: WHO, 2010. http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf.
World Health Organization (WHO). Anti-tuberculosis drug resistance in the world: fourth global report. Geneva: WHO; 2008. WHO/HTM/TB/2008.394
Jacobs TQ. Adverse effects profile of multidrug-resistant tuberculosis treatment in a South African outpatient clinic, S AfrFamPract. 2012; 54(6):531-539
Törün T, Güngör G,Özmen, etal. Side effects associated with the treatment of multidrug-resistant tuberculosis. INT J TUBERC LUNG DIS. 2005; 9(12):1373–1377
Goble etal. Tuberculosis resistant to ionized and refampin, Massachusetts. The New England Journal of Medicine. 328(8).
Furin JJ, Mitnick CD, Shin SS, et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2001; 5(7):648-655.
Bloss E, etal. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004. Int J Tuberc Lung Dis. 2010; 14(3):275-81
Da XueXueBao. Liver injury associated with treatment of multidrug-resistant tuberculosis: a systematic review and meta-analysis. Jornal of Peking University, Beijing. 2014; 46(3):417-23
Kargar M, et.al. Anti-tuberculosis drugs adverse reactions: a review of the Iranian literature. Expert Opin Drug Saf. 2014; 13(7):875-91. doi: 10.1517/14740338.2014.925443.
Van der Walt M, Lancaster J, Odendaal R, Davis JG, Shean K, et al. Serious Treatment Related Adverse Drug Reactions amongst Anti-Retroviral Naı¨ve MDR-TB Patients. PLoS ONE. 2013; 8(4): e58817. doi:10.1371/journal.pone.0058817
Bharty S, Prakash B, Saraf S, Rai R, Bhatnagar AK, Gupta UA. Initiation of MDR TB treatment: is hospitalization worth?.Indian J Tuberc. 2014; 61(1): 57-64
Bezu, H., Seifu, D., Yimer, G. and Mebrhatu, T. (2014) Prevalence and Risk Factors of Adverse Drug Reactions Associated Multidrug Resistant Tuberculosis Treatments in Selected Treatment Centers in Addis Ababa Ethiopia. Journal of Tuberculosis Research. 2014; 2, 144-154. http://dx.doi.org/10.4236/jtr.2014.23018
Castañeda C, Sanchez E, Acha J, Farmer P.E,Kim J.Y. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. INT J TUBERC LUNG DIS. 2001; 5(7):648–655
Goble M, Iseman M D, Madsen L A, Waite D, Ackerson L, Horsburgh C R Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527–532.
Mohammad A. Tag El Din, Ashraf A. El Maraghy, Abdel Hay R, Abdel Hay. Adverse reactions among patients being treated formulti-drug resistant tuberculosis at Abbassia ChestHospital. Egyptian Journal of Chest Diseases and Tuberculosis. 2015; 64, 939–952
Moore R D, Smith C R, Lietman P S. Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. J Infect Dis 1984; 149: 23–30.
Rathod KB et al. Adverse events among patients of multi drug resistant tuberculosis receiving second line anti TB treatment. Int J Sci Rep. 2015, 1(6):253-257 http://www.sci-rep.com
Sonya Shin; Jennifer Furin; FélixAlcántara; Anne Hyson; Keith Joseph; EpifanioSánchez; Michael Rich. Hypokalemia among Patients Receiving Treatment for Multidrug-Resistant Tuberculosis. Chest. 2004; 125(3):974-980. doi:10.1378/chest.125.3.974
Isaakidis P, Varghese B, Mansoor H, Cox HS, Ladomirska J, et al. Adverse Events among HIV/MDR-TB Co-Infected Patients Receiving Antiretroviral and Second Line Anti-TB Treatment in Mumbai, India. PLoSOne. 2012; 7(7): e40781. doi:10.1371/journal.pone.0040781
Isaakidis P, et al. Experiences of patients with HIV and MDR-TB. Tropical Medicine and International Health. https://www.ghdonline.org/uploads/I_cry_everyday_1.pdf
Brust, et al. Adverse events in an integrated, home-based treatment program for MDR-TB and HIV in KwaZulu-Natal, South Africa. J Acquir Immune DeficSyndr. 2013; 62(4): 436–440. doi:10.1097/QAI.0b013e31828175ed
Riza et al. Clinical management of concurrent diabetes and tuberculosis and the implications for patient services. Lancet Diabetes Endocrinol. 2014; 2(9): 740–753. doi:10.1016/S2213-8587(14)70110-X.
Chung-Delgado K, Revilla-Montag A, Guillen-Bravo S, Velez-Segovia E, Soria-Montoya A, et al. Factors Associated with Anti-Tuberculosis Medication Adverse Effects: A Case-Control Study in Lima, Peru. PLoS ONE. 2011; 6(11): e27610. doi:10.1371/journal.pone.0027610